Tvardi Therapeutics Net Profit Margin Growth & History (TVRD)
Tvardi Therapeutics's net profit margin was −411.90% for fiscal 2024.
View full Tvardi Therapeutics company overviewTvardi Therapeutics annual net profit margin history
| Fiscal year | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| 2024 | 2024-12-31 | −411.90% | +153.31 pp |
| 2023 | 2023-12-31 | −565.21% | −361.05 pp |
| 2022 | 2022-12-31 | −204.16% | +179.90 pp |
| 2021 | 2021-12-31 | −384.06% | −390.28 pp |
| 2020 | 2020-12-31 | 6.23% | +541.14 pp |
| 2019 | 2019-12-31 | −534.91% | +14.59 pp |
| 2018 | 2018-12-31 | −549.51% | +5830.84 pp |
| 2017 | 2017-12-31 | −6,380.35% | +60224.30 pp |
| 2016 | 2016-12-31 | −66,604.65% | −65955.43 pp |
| 2015 | 2015-12-31 | −649.22% | −90.68 pp |
| 2014 | 2014-12-31 | −558.55% | −525.42 pp |
| 2013 | 2013-12-31 | −33.12% | +493.85 pp |
| 2012 | 2012-12-31 | −526.97% | — |
Tvardi Therapeutics quarterly net profit margin
| Fiscal quarter | Period ended | Net profit margin | Change (percentage points) |
|---|---|---|---|
| Q1 2025 | 2025-03-31 | −372.87% | −176.05 pp |
| Q4 2024 | 2024-12-31 | −873.33% | +203.13 pp |
| Q3 2024 | 2024-09-30 | −215.69% | +360.39 pp |
| Q2 2024 | 2024-06-30 | −703.83% | −249.79 pp |
| Q1 2024 | 2024-03-31 | −196.81% | +235.71 pp |
| Q4 2023 | 2023-12-31 | −1,076.46% | −146.11 pp |
| Q3 2023 | 2023-09-30 | −576.08% | −361.71 pp |
| Q2 2023 | 2023-06-30 | −454.05% | −435.76 pp |
| Q1 2023 | 2023-03-31 | −432.52% | +146.79 pp |
| Q4 2022 | 2022-12-31 | −930.36% | +3135.66 pp |
| Q3 2022 | 2022-09-30 | −214.37% | −209.37 pp |
| Q2 2022 | 2022-06-30 | −18.28% | — |
| Q1 2022 | 2022-03-31 | −579.31% | +624.87 pp |
| Q4 2021 | 2021-12-31 | −4,066.02% | −4136.42 pp |
| Q3 2021 | 2021-09-30 | −5.00% | +173.17 pp |
| Q1 2021 | 2021-03-31 | −1,204.19% | −846.82 pp |
| Q4 2020 | 2020-12-31 | 70.40% | +704.65 pp |
| Q3 2020 | 2020-09-30 | −178.17% | +389.54 pp |
| Q2 2020 | 2020-06-30 | −444.94% | −4.08 pp |
| Q1 2020 | 2020-03-31 | −357.37% | +143.77 pp |
| Q4 2019 | 2019-12-31 | −634.25% | −261.00 pp |
| Q3 2019 | 2019-09-30 | −567.71% | −184.46 pp |
| Q2 2019 | 2019-06-30 | −440.86% | +157.40 pp |
| Q1 2019 | 2019-03-31 | −501.14% | — |
| Q4 2018 | 2018-12-31 | −373.25% | — |
| Q3 2018 | 2018-09-30 | −383.25% | — |
| Q2 2018 | 2018-06-30 | −598.26% | — |
| Q1 2017 | 2017-03-31 | −2,437.32% | +150305.54 pp |
| Q2 2016 | 2016-06-30 | −16,550.63% | −15900.29 pp |
| Q1 2016 | 2016-03-31 | −152,742.86% | −151783.96 pp |
| Q3 2015 | 2015-09-30 | −196.19% | +385.59 pp |
| Q2 2015 | 2015-06-30 | −650.34% | −270.66 pp |
| Q1 2015 | 2015-03-31 | −958.90% | +941.67 pp |
| Q4 2014 | 2014-12-31 | −456.46% | −241.35 pp |
| Q3 2014 | 2014-09-30 | −581.78% | −132.37 pp |
| Q2 2014 | 2014-06-30 | −379.69% | −433.20 pp |
| Q1 2014 | 2014-03-31 | −1,900.56% | — |
| Q4 2013 | 2013-12-31 | −215.11% | — |
| Q3 2013 | 2013-09-30 | −449.41% | — |
| Q2 2013 | 2013-06-30 | 53.51% | — |
Tvardi Therapeutics net profit margin trends
Over the last five fiscal years, Tvardi Therapeutics's net profit margin increased from −534.91% to −411.90%, a change of +123.02 percentage points. The latest reported quarter, Q1 2025, shows −372.87%.
What net profit margin means
Net profit margin measures the percentage of revenue remaining as net income after operating costs, interest, taxes, and other expenses. It shows how much bottom-line profit or loss a company generates from each dollar of revenue.
How net profit margin is calculated
TickerStat calculates net profit margin as SEC-reported net income divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Tvardi Therapeutics source filings ↗